Recombinant Bovine Diacylglycerol O-acyltransferase 2 (DGAT2)

What is the primary function of bovine DGAT2 in lipid metabolism?

Bovine DGAT2 catalyzes the final and committed step of triacylglycerol (TG) biosynthesis by transferring an acyl group from acyl-CoA to diacylglycerol (DAG). This enzyme is critical for the synthesis of triacylglycerols, which are major components of intramuscular fat in cattle. The rate of TAG synthesis is largely determined by DGAT2 expression levels, making it a rate-limiting enzyme in this pathway. DGAT2 primarily functions in the endoplasmic reticulum (ER) under normal conditions but can relocate to lipid droplets when cells are incubated with fatty acids, enabling localized TG synthesis for lipid droplet expansion .

How does the structure of recombinant bovine DGAT2 influence its function?

Recombinant bovine DGAT2 is an integral membrane protein with two transmembrane domains that are essential for its functionality. These domains are particularly important for protein-protein interactions, as demonstrated in deletion mutagenesis studies where removal of these transmembrane regions disrupted DGAT2's ability to interact with other proteins such as MGAT2. The structural arrangement of DGAT2 facilitates the formation of both homodimers (~90 kDa) and larger protein complexes (~650 kDa), which have been confirmed through chemical cross-linking experiments using disuccinimidyl suberate (DSS) . This oligomerization appears to be important for coordinating triacylglycerol synthesis with other lipid metabolism enzymes.

What expression systems are most effective for producing recombinant bovine DGAT2?

The most effective expression systems for producing functional recombinant bovine DGAT2 include mammalian cell lines like HEK-293T, COS-7, and McArdle RH7777 cells. These systems provide the appropriate post-translational modifications and membrane environment required for proper DGAT2 folding and activity. For transient transfection, a protocol using polyethylenimine has proven effective: 20 μg of DGAT2 plasmid DNA should be incubated with 430 μl of 0.15 M NaCl and 120 μl of 0.1% polyethylenimine (pH 7.0) for 10 minutes at room temperature before adding to cells at approximately 50% confluency . This approach typically yields functional protein expression within 24-48 hours. Alternative expression systems such as insect cells can be used, but mammalian systems generally provide protein with higher enzymatic activity due to more appropriate post-translational modifications.

What are the most reliable methods for assessing DGAT2 enzyme activity in vitro?

The most reliable methods for assessing recombinant bovine DGAT2 enzyme activity in vitro involve measuring the incorporation of radiolabeled substrates into triacylglycerol. A standard assay utilizes [14C]oleoyl-CoA and diacylglycerol as substrates, with the reaction products separated by thin-layer chromatography and quantified by scintillation counting. For a more high-throughput approach, fluorescently labeled acyl-CoA analogs can be used, with product formation measured by HPLC or fluorescence detection.

When assessing DGAT2 activity in cellular contexts, researchers commonly measure intracellular triacylglycerol (TAG) content following DGAT2 overexpression or knockdown. Studies have demonstrated that DGAT2 overexpression significantly increases intracellular TAG content (p < 0.05) in bovine preadipocytes, while DGAT2 knockdown reduces TAG accumulation . These functional assays should be complemented with appropriate controls and validation of DGAT2 expression levels via Western blotting to ensure result reliability.

How can protein-protein interactions of DGAT2 be effectively studied?

Protein-protein interactions of bovine DGAT2 can be effectively studied through multiple complementary approaches:

• Chemical cross-linking: Using membrane-permeable cross-linkers such as disuccinimidyl suberate (DSS) at concentrations between 10-500 μM. This approach has successfully demonstrated that DGAT2 forms both dimers (~90 kDa) and larger protein complexes (~650 kDa) .

• Co-immunoprecipitation: Using epitope-tagged DGAT2 (e.g., FLAG-tagged) to pull down interacting proteins, followed by immunoblotting to detect specific binding partners. This method has confirmed the interaction between DGAT2 and MGAT2 .

• In situ proximity ligation assay: This technique allows visualization of protein interactions in their native cellular environment and has been successfully applied to detect DGAT2-MGAT2 interactions .

• Fluorescence microscopy with co-localization analysis: Co-expression of fluorescently tagged DGAT2 with potential interacting partners allows for assessment of spatial proximity within cellular compartments including the ER and lipid droplets.

These methods should be used in combination to provide robust evidence of protein interactions, as each approach has distinct strengths and limitations.

What protocols are recommended for generating DGAT2 mutants for structure-function analysis?

For structure-function analysis of bovine DGAT2, site-directed mutagenesis using PCR-based methods with PfuUltra DNA polymerase has proven effective. The recommended protocol includes:

• Design primers containing the desired mutation flanked by 15-20 nucleotides of correct sequence on each side

• Perform PCR using plasmid containing wild-type DGAT2 as template

• Treat amplified product with DpnI to digest methylated parental DNA

• Transform competent E. coli with the reaction mixture

• Select and screen colonies for the presence of mutations by sequencing

• Validate mutant protein expression by Western blotting following transfection into mammalian cells

Deletion mutagenesis has revealed that the two transmembrane domains of DGAT2 are particularly important for its interaction with MGAT2 . When designing DGAT2 mutants, researchers should consider targeting conserved motifs, potential catalytic residues, and regions involved in protein-protein interactions or subcellular localization. Following mutagenesis, comprehensive functional assessment should include enzyme activity assays, subcellular localization studies, and protein interaction analyses to fully characterize the impact of mutations.

How does DGAT2 regulate bovine preadipocyte differentiation?

DGAT2 plays a crucial regulatory role in bovine preadipocyte differentiation through multiple mechanisms:

• Upregulation of adipogenic transcription factors: DGAT2 overexpression significantly increases (p < 0.05) the expression of key adipogenic factors including PPARγ, C/EBPα, and SREBF1, which are master regulators of adipocyte differentiation .

• Promotion of lipid droplet formation: High expression of DGAT2 directly promotes lipid droplet formation and triglyceride accumulation in bovine preadipocytes, which are hallmarks of adipocyte maturation .

• Modulation of signaling pathways: Transcriptomic analysis has revealed that DGAT2 influences multiple signaling pathways involved in adipogenesis, including PPAR signaling, AMPK pathways, and fatty acid biosynthesis pathways .

The regulatory effect of DGAT2 appears to be bidirectional, as DGAT2 knockdown reduces intracellular TAG and lipid droplet content while downregulating (p < 0.05) adipogenic factors such as C/EBPβ and lipogenic enzymes including LPIN1 and ACACA . This suggests that DGAT2 is not merely a downstream effector but also plays a feedforward role in promoting the entire adipogenic program.

What transcriptomic changes occur in bovine adipocytes following DGAT2 overexpression?

Key pathways enriched among these DEGs include:

• PPAR signaling pathway - critical for adipogenesis

• AMP-activated protein kinase pathway - regulator of cellular energy homeostasis

• Cholesterol metabolism - related to membrane biogenesis during adipocyte formation

• Fatty acid biosynthesis - essential for triglyceride formation

In contrast, DGAT2 knockdown resulted in 378 DEGs (230 upregulated, 148 downregulated) compared to controls . These DEGs were enriched in pathways that negatively regulate adipogenesis, including:

• Hippo signaling pathway - inhibits adipogenesis by suppressing PPARγ activity

• TGF-β signaling pathway - limits differentiation potential of preadipocytes

• cAMP signaling pathway - modulates cellular metabolism and differentiation

These transcriptomic changes highlight DGAT2's role as a key regulator of bovine adipocyte differentiation through multiple cellular pathways.

What methodological approaches can be used to study DGAT2's role in bovine fat metabolism?

To comprehensively study DGAT2's role in bovine fat metabolism, researchers should employ a multi-tiered methodological approach:

• Genetic manipulation of DGAT2 expression:

  • Overexpression using adenoviral vectors (such as Ad-DGAT2) with titers of approximately 1 × 10^9 PFU/mL

  • RNA interference using shRNA targeting the CDS region of DGAT2 (effective targets include positions 108, 320, and 687 in the Yanbian cattle DGAT2 sequence)

• Lipid content analysis:

  • Measurement of intracellular triacylglycerol using enzymatic kits

  • Visualization and quantification of lipid droplets using Oil Red O staining

  • Assessment of adiponectin levels as markers of adipocyte maturation

• Gene expression analysis:

  • qRT-PCR for adipogenic transcription factors (PPARγ, C/EBPα, C/EBPβ)

  • Western blotting for lipid metabolism enzymes (DGAT1, LPIN1, GPAT4)

  • RNA sequencing for comprehensive transcriptomic profiling

• Pathway analysis:

  • KEGG pathway enrichment analysis of differentially expressed genes

  • Validation of key pathway components through inhibitor studies

  • Protein-protein interaction mapping using co-immunoprecipitation and proximity ligation assays

This integrated approach has successfully demonstrated that DGAT2 regulates preadipocyte differentiation and lipid accumulation by mediating the expression of genes related to adipose differentiation, lipid metabolism, and fatty acid synthesis .

How does DGAT2 interact with MGAT2 to coordinate triacylglycerol synthesis?

DGAT2 and MGAT2 interact in a coordinated manner to enhance triacylglycerol synthesis through substrate channeling. Co-immunoprecipitation experiments and in situ proximity ligation assays have demonstrated that these enzymes physically interact . This interaction is dependent on the two transmembrane domains of DGAT2, as deletion mutagenesis studies have shown that these domains are essential for MGAT2 binding .

The functional significance of this interaction is evident in co-expression studies, where simultaneous expression of DGAT2 and MGAT2 results in increased TG storage compared to expression of either enzyme alone . This synergistic effect likely occurs because MGAT2 synthesizes diacylglycerol, which is then directly utilized by DGAT2 for triacylglycerol synthesis without requiring diffusion of the intermediate substrate. The spatial arrangement of this enzyme complex facilitates efficient substrate channeling, as both enzymes co-localize in the ER and on lipid droplets .

Importantly, when McArdle rat hepatoma RH7777 cells are incubated with 2-monoacylglycerol, DGAT2 translocates to lipid droplets and forms large cytosolic lipid droplets, indicating that DGAT2 can efficiently utilize monoacylglycerol-derived diacylglycerol produced by MGAT2 . This dynamic interaction demonstrates how lipid synthesis enzymes form functional complexes to enhance metabolic efficiency.

What factors influence DGAT2 translocation between the ER and lipid droplets?

The translocation of DGAT2 between the endoplasmic reticulum and lipid droplets is influenced by several key factors:

• Fatty acid availability: When cells are incubated with oleate or other fatty acids, DGAT2 relocates from the ER to lipid droplets to facilitate localized triacylglycerol synthesis . This substrate-driven translocation appears to be a regulatory mechanism to enhance lipid storage when fatty acid supply is abundant.

• Monoacylglycerol exposure: Incubation of cells with 2-monoacylglycerol triggers DGAT2 translocation to lipid droplets, suggesting that substrate intermediates in the glycerolipid synthesis pathway can influence DGAT2 localization .

• Protein interactions: The association of DGAT2 with other enzymes such as MGAT2 may facilitate its translocation between cellular compartments, as co-expression studies have shown that these proteins co-localize on both the ER and lipid droplets .

• Oligomerization state: Chemical cross-linking experiments have revealed that DGAT2 forms dimers and larger protein complexes on both the ER and lipid droplets, with potentially differential oligomerization patterns between these compartments. More DGAT2 dimer has been observed in the lipid droplet fraction compared to membrane fractions , suggesting that the oligomerization state may influence subcellular localization.

Interestingly, studies have shown that while fatty acid availability triggers DGAT2 translocation, stimulating TG synthesis with oleate does not appear to increase DGAT2 oligomer abundance . This suggests that the translocation and oligomerization of DGAT2 may be regulated by distinct mechanisms.

How can chemical cross-linking be optimized to study DGAT2 protein complexes?

Optimizing chemical cross-linking for studying DGAT2 protein complexes requires careful consideration of multiple parameters:

• Cross-linker selection and concentration: Disuccinimidyl suberate (DSS) has proven effective for DGAT2 complex analysis. Titration experiments have shown that DSS concentrations between 10-500 μM are suitable, with higher concentrations resulting in decreased monomeric DGAT2 abundance and increased complex formation . A concentration-dependent approach is recommended to capture different oligomeric states.

• Sample preparation conditions:

  • For membrane preparations: Total cellular membranes should be resuspended at 1 μg/μl protein in 10 mM Hepes (pH 7.4)/1 mM EDTA buffer

  • For intact cells: Cells should be washed with PBS before cross-linker application

  • For lipid droplet fractions: Cells should first be incubated with 0.5 mM oleate for 12h to stimulate lipid droplet formation before cross-linking

• Reaction conditions: Cross-linking reactions should proceed for 30 minutes at room temperature and be terminated by adding 1/10 volume of 1 M Tris-Cl (pH 8.0) .

• Analysis methods: SDS-PAGE using gradient gels (4-20%) is recommended for resolving high molecular weight complexes, followed by immunoblotting with antibodies against epitope tags (e.g., anti-FLAG) or specific DGAT2 antibodies.

• Controls: Parallel samples without cross-linker and samples with irrelevant membrane proteins should be included as controls for specificity.

This optimized cross-linking approach has successfully demonstrated that DGAT2 forms both dimers (~90 kDa) and larger protein complexes (~650 kDa) in membranes and on lipid droplets , providing valuable insights into the quaternary structure of this important lipid synthesis enzyme.

What is the rationale for targeting DGAT2 in metabolic disorders?

The rationale for targeting bovine DGAT2 in metabolic disorders stems from its critical role as the rate-limiting enzyme in triacylglycerol synthesis. DGAT2 overexpression significantly increases intracellular TAG, adiponectin, and lipid droplet contents (p < 0.05), while also upregulating adipogenic and lipogenic gene expression . Conversely, DGAT2 inhibition or knockdown reduces lipid accumulation, making it a promising therapeutic target for conditions characterized by excessive fat deposition.

In human clinical research, DGAT2 inhibitors are being evaluated for treating non-alcoholic steatohepatitis (NASH) and liver fibrosis . The scientific rationale includes:

• Reduction of hepatic triglyceride accumulation: By inhibiting the final step of TG synthesis, DGAT2 inhibitors can potentially reduce hepatic steatosis

• Modulation of metabolic signaling pathways: DGAT2 influences PPAR signaling, AMPK pathways, and fatty acid metabolism

• Targeted approach: Unlike broader metabolic interventions, DGAT2 inhibition specifically targets triglyceride synthesis without necessarily affecting other essential lipid pathways

Phase II clinical trials are evaluating DGAT2 inhibitors alone or in combination with other agents (such as ACCi) in adults with biopsy-confirmed NASH and liver fibrosis stages 2-3 . While this research is primarily focused on human applications, the insights gained from bovine DGAT2 studies provide valuable comparative information on the fundamental biology of this enzyme across species.

How can recombinant bovine DGAT2 be used to screen for potential inhibitors?

Recombinant bovine DGAT2 provides an excellent platform for screening potential inhibitors through the following methodological approaches:

• In vitro enzyme assays: Purified recombinant bovine DGAT2 can be used in biochemical assays measuring the conversion of diacylglycerol and acyl-CoA to triacylglycerol. Inhibitor candidates can be evaluated based on their IC50 values and inhibition kinetics. The assay typically utilizes [14C]oleoyl-CoA as a substrate, with products separated by thin-layer chromatography.

• Cell-based assays with overexpressed DGAT2: HEK-293T, COS-7, or McArdle RH7777 cells transfected with bovine DGAT2 can be used to screen compounds in a cellular context. Following treatment with potential inhibitors, researchers can measure:

  • Intracellular triacylglycerol content

  • Lipid droplet formation visualized by microscopy

  • Expression of lipogenic genes regulated by DGAT2

• Protein interaction disruption assays: Since DGAT2 forms complexes with MGAT2 and other proteins , compounds that disrupt these interactions may serve as allosteric inhibitors. Co-immunoprecipitation or proximity ligation assays can detect such disruptions.

• Structure-guided screening: Although a complete crystal structure of bovine DGAT2 is not available, homology models based on related acyltransferases can guide rational inhibitor design. Virtual screening followed by experimental validation has proven successful for related enzymes.

When screening inhibitors, it's important to establish both bovine and human DGAT2 assays to identify species-specific differences in inhibitor sensitivity, as these may impact translational research. Additionally, counter-screening against DGAT1 is essential to identify inhibitors with selectivity for DGAT2.

What considerations are important when designing clinical studies involving DGAT2 inhibitors?

When designing clinical studies involving DGAT2 inhibitors, several important considerations should be addressed based on current research approaches:

• Patient selection and stratification: Current phase II studies evaluating DGAT2 inhibitors in NASH employ a triage approach with double-confirmation via non-invasive markers prior to screening/baseline liver biopsy . This methodology ensures appropriate patient selection and reduces unnecessary invasive procedures.

• Dosing strategy: Studies are evaluating DGAT2 inhibitors at multiple dose levels (25–300 mg BID or 150–300 mg once daily), highlighting the importance of dose-ranging approaches to identify optimal therapeutic windows .

• Combination therapy potential: Co-administration strategies, such as DGAT2i (150–300 mg BID) + ACCi (5–10 mg BID), should be considered based on preclinical evidence of enhanced efficacy with combination approaches .

• Study duration: Current trials employ a 48-week double-blind, double-dummy dosing period following a ≥6-week run-in period , reflecting the chronic nature of metabolic disorders and the time required to observe meaningful histological changes.

• Biomarker selection: Both invasive (liver biopsy) and non-invasive biomarkers should be incorporated to comprehensively assess treatment effects on:

  • Hepatic fat content (quantitative imaging)

  • Inflammatory markers

  • Fibrosis markers

  • Metabolic parameters (lipid profiles, insulin sensitivity)

• Safety monitoring: Special attention should be paid to potential off-target effects, particularly in adipose tissue, skeletal muscle, and cardiac tissue, where altered lipid metabolism might have unintended consequences.

• Cross-species considerations: Insights from bovine DGAT2 research should inform human studies, particularly regarding potential species differences in enzyme function, regulation, and inhibitor sensitivity.

This structured approach to clinical study design reflects the complexity of targeting lipid metabolism enzymes and the need for comprehensive assessment of both efficacy and safety parameters.

What are the knowledge gaps in understanding the regulation of bovine DGAT2?

Despite significant advances in bovine DGAT2 research, several critical knowledge gaps remain:

• Post-translational modifications: The role of phosphorylation, glycosylation, and other modifications in regulating bovine DGAT2 activity and localization remains poorly characterized. Identification of specific modification sites and their functional consequences would enhance our understanding of DGAT2 regulation.

• Transcriptional control mechanisms: While DGAT2 overexpression affects numerous downstream genes, the upstream transcription factors and epigenetic mechanisms controlling DGAT2 expression in different bovine tissues are not fully elucidated.

• Tissue-specific isoforms and splice variants: Potential tissue-specific variants of DGAT2 in different bovine tissues (adipose, liver, mammary gland) may have distinct regulatory properties that remain to be characterized.

• Breed-specific variations: Studies in Yanbian cattle have provided valuable insights , but comprehensive comparative analyses across different cattle breeds are needed to understand genetic variations that might influence DGAT2 function and regulation.

• Nutritional and hormonal regulation: The influence of different dietary components and hormonal states on bovine DGAT2 expression and activity requires further investigation, particularly in the context of feeding regimens relevant to beef production.

• Interaction with lipid droplet proteins: While DGAT2 relocates to lipid droplets, its interactions with lipid droplet-specific proteins (perilipins, ATGL, etc.) in bovine cells remain to be fully characterized.

Addressing these knowledge gaps would provide a more comprehensive understanding of bovine DGAT2 regulation and potentially reveal novel approaches for modulating its activity in agricultural and biomedical applications.

How might gene editing technologies be applied to study DGAT2 function in bovine models?

Gene editing technologies offer powerful approaches for studying DGAT2 function in bovine models:

• CRISPR-Cas9 for precise genomic modifications:

  • Generation of knockout bovine cell lines by targeting critical exons of DGAT2

  • Introduction of point mutations to study structure-function relationships

  • Creation of reporter gene knock-ins to monitor DGAT2 expression in real-time

  • Engineering of tagged DGAT2 variants at endogenous loci for protein localization studies

• Base editing and prime editing applications:

  • Introduction of specific amino acid substitutions without double-strand breaks

  • Correction or introduction of naturally occurring bovine DGAT2 variants

  • Modification of regulatory elements controlling DGAT2 expression

• Inducible expression systems:

  • Development of doxycycline-inducible DGAT2 expression to study temporal aspects of its function

  • Tissue-specific promoters to restrict DGAT2 manipulation to adipose, liver, or other relevant tissues

• High-throughput screening approaches:

  • CRISPR interference (CRISPRi) or activation (CRISPRa) libraries targeting DGAT2 regulators

  • Pooled CRISPR screens to identify synthetic lethal interactions with DGAT2

• In vivo applications:

  • Generation of bovine embryos with DGAT2 modifications using somatic cell nuclear transfer

  • Ex vivo editing of bovine adipose tissue explants to study DGAT2 in a more physiological context

These approaches would complement existing methods and provide more precise tools for understanding DGAT2's role in bovine lipid metabolism, potentially leading to applications in animal agriculture for improving meat quality through targeted modification of intramuscular fat deposition.

What emerging technologies could advance our understanding of DGAT2 in spatial and temporal contexts?

Several emerging technologies have the potential to significantly advance our understanding of DGAT2 in spatial and temporal contexts:

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, PALM) to visualize DGAT2 localization beyond the diffraction limit

  • Correlative light and electron microscopy (CLEM) to connect DGAT2 localization with ultrastructural features

  • Live-cell imaging with genetically encoded fluorescent tags to track DGAT2 dynamics in real-time

  • FRET/FLIM approaches to monitor DGAT2 protein interactions with nanometer resolution

• Spatial transcriptomics and proteomics:

  • Single-cell RNA sequencing of bovine adipose tissue to capture heterogeneity in DGAT2 expression

  • Spatial proteomics to map DGAT2 protein distribution across subcellular compartments

  • Proximity labeling approaches (BioID, APEX) to identify proteins in the vicinity of DGAT2 within specific organelles

• Metabolic flux analysis:

  • Stable isotope-labeled substrates combined with mass spectrometry to track lipid metabolism dynamics

  • Computational modeling of DGAT2-mediated metabolic flux under different physiological conditions

  • Integration of lipidomics data with DGAT2 expression/activity for systems-level understanding

• Organoid and microphysiological systems:

  • Bovine adipose or liver organoids to study DGAT2 in a 3D tissue-like environment

  • Organ-on-chip technologies to investigate DGAT2 in the context of tissue-tissue interactions

  • Bioprinting approaches to create defined spatial arrangements of cells expressing different levels of DGAT2

• Optogenetic and chemogenetic tools:

  • Light-controllable DGAT2 expression or activity to study temporal aspects of lipid metabolism

  • Rapidly inducible protein degradation systems to acutely deplete DGAT2

These emerging technologies would provide unprecedented insights into how DGAT2 functions within the complex spatial architecture of cells and tissues, and how its activity changes over time in response to various physiological stimuli, advancing both basic science understanding and potential applications in agricultural and biomedical fields.